Neoantigen T cell therapy for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized T cell therapy designed to target specific markers on your cancer cells (neoantigens). It is for people with advanced gastric cancer who have tried standard treatments and have no other effective options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced gastric cancer and have already received standard treatments, with no effective treatment left.
- You have at least one tumor that can be measured on a scan.
- Your expected survival is at least 5 months.
- You are in fairly good overall health (ECOG score 0, 1, or 2).
- Your blood cell counts and liver/kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
This trial tests a combination of short-course radiation, standard chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with advanced or metastatic gastric cancer that hasn't spread to lymph nodes. The goal is to see if this approach can help shrink or control the tumor.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial is testing a personalized treatment approach for advanced gastric cancer. It uses unique markers in your tumor (HER2, CLDN18.2, PD-L1) to match you with targeted therapies, aiming for better results than standard chemotherapy.
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to seek out and kill cancer cells in the low-oxygen environment of tumors. It is for people with advanced stomach cancer that has not responded to standard treatments.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.